RTP Mobile Logo
What Clinicians Want to Know: Addressing the Most Common Questions and Controversies in the Current Clinical Management of Select Hematologic Cancers (Audio Program)
Released October 2011

Featuring interviews with Drs Antonio Palumbo, Susan M O’Brien, John P Leonard, Lauren C Pinter-Brown and Sergio Giralt focused on NHL, CML, CLL and multiple myeloma. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Hematologic oncology is one of the most rapidly evolving areas in cancer medicine as additional agents and new data regarding existing therapies are emerging seemingly every day. Integrating this information into established treatment strategies may be a considerable challenge for the practicing hematologist and medical oncologist. To address that challenge, this activity features one-on-one interviews with 5 investigators attempting to address the most common and/or ambiguous clinical concerns facing practitioners who care for patients with common hematologic cancers, including non-Hodgkin lymphoma (NHL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML). The topics discussed during the program are based on the results of a national survey of hematologic oncologists in the United States and the contributions of attendees at a recent CME symposium and represent a broad array of specific questions and clinical scenarios for which these individuals want to receive additional education and perspectives. Thus, the activity is intended to assist medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies to facilitate optimal patient care.

    LEARNING OBJECTIVES

    • Demonstrate knowledge of prognostic and predictive molecular markers of clinical relevance to the treatment of commonly encountered hematologic cancers.
    • Develop a therapeutic algorithm for the clinical management of indolent and aggressive forms of B-cell NHL.
    • Explain the risks and benefits of evidence-based treatment approaches and agents to patients with T-cell lymphoma requiring systemic therapy.
    • Apply the results of emerging clinical research to the selection of oral or intravenous cytotoxic and/or biologic regimens for patients with CLL.
    • Consider known toxicity profiles of BCR-ABL targeted therapies to individualize the selection of these agents for initial and subsequent management of CML.
    • Compare and contrast the benefits and risks of immunomodulatory agents, proteasome inhibitors or both as systemic treatment for active MM.
    • Identify patients with MM who may benefit from maintenance systemic treatment in both the post-transplant and nontransplant settings.
    • Recall the ongoing clinical trials evaluating innovative investigational approaches for diverse hematologic diseases, and enroll appropriate patients for study participation.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY


    CME credit is no longer available for this issue

    This CME activity contains an audio component. The participant should listen to the audio MP3s.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr O’Brien had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr PalumboAdvisory Committee and Consulting Agreements: Amgen Inc, Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc. Dr Leonard Consulting Agreements: Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi. Dr Pinter-BrownAdvisory Committee: Allos Therapeutics, Celgene Corporation, Genentech BioOncology, Millennium: The Takeda Oncology Company; Consulting Agreement: Allos Therapeutics; Speakers Bureau: Genentech BioOncology. Dr GiraltAdvisory Committee and Speakers Bureau: Amgen Inc, Celgene Corporation, Genzyme Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Allos Therapeutics, Cephalon Inc, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company, Mundipharma International Limited and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: October 2011
    Expiration date: October 2012

Acknowledge and close

Listen to audio:
What Clinicians Want to Know: Addressing the Most Common Questions and Controversies in the Current Clinical Management of Select Hematologic Cancers (Audio Program)
Released October 2011

Featuring interviews with Drs Antonio Palumbo, Susan M O’Brien, John P Leonard, Lauren C Pinter-Brown and Sergio Giralt focused on NHL, CML, CLL and multiple myeloma. (Audio Content)

Read print: